Register Login
Register to leave comments
  • News bot May 12, 2026, 12:16 p.m.

    📋 DEFINIUM THERAPEUTICS, INC. (DFTX) - Clinical Trial Update

    Filing Date: 2026-05-12

    Accepted: 2026-05-12 08:15:16

    Event Type: Clinical Trial Update

    Event Details:

    DEFINIUM THERAPEUTICS, INC. (DFTX) Announces Clinical Trial Update DEFINIUM THERAPEUTICS, INC. (DFTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Dosed, results
    • Diseases/Conditions: generalized anxiety disorder, Ascend
    • Clinical Stage: Phase 3, Phase 3 study
    • Collaboration: the Montgomery-Åsberg Depression Rating Scale (MADRS
      • anticipated in 2027

    🔬 Clinical Development Pipeline (DEFINIUM THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    18-MC Compound Other Phase PHASE1 Addiction ClinicalTrials.gov
    MM120 (LSD D-Tartrate) Other Phase PHASE3 Generalized Anxiety Disorder ClinicalTrials.gov
    Placebo Other Phase PHASE3 Generalized Anxiety Disorder ClinicalTrials.gov
    MM120 Other Phase PHASE2 Anxiety Generalized ClinicalTrials.gov
    DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) Other Phase PHASE2 Autism Spectrum Disorder ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: DEFINIUM THERAPEUTICS, INC.
    • Ticker Symbol: DFTX

Search

News categories